Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124560
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Post-Acute COVID-19 Syndrome
A Study of Apabetalone in Subjects With Long -COVID
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed…
- Trial name
- NCT06590324
- Testing
- Apabetalone
- Where
- 3 sites in Jordan, Saudi Arabia and 1 more
- Volunteers
- 200 people
- Sponsor
- Resverlogix Corp
Diabetes, Diabetes Mellitus, Type 2
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart 70 + biphasic insulin aspart 30 with biphasic human insulin 30 in subjects with type 2 diabetes.
- Trial name
- NCT01526980
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70, biphasic human insulin 30
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Glucose Intolerance, Diabetes Mellitus, Type 2
Effects of Seaweed Extract on Blood Glucose Response to Sucrose
This study will examine the impact of the seaweed (Ascophyllum nodosum) extract on blood glucose levels after a sugary drink in healthy subjects.
- Conditions
- Glucose Intolerance, Diabetes Mellitus, Type 2, Healthy Diet, Postprandial Hyperglycemia
- Trial name
- NCT05461560
- Testing
- Sucrose solution, Seaweed extract in sucrose solution
- Where
- Ireland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Type 2 Diabetes Mellitus
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
- Trial name
- T2DM (NCT04100473)
- Testing
- Inhaled Human Insulin, Insulin Lispro (Humalog U-100)
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Dance Biopharm Inc.
Type II Diabetes Mellitus
Pharmacokinetics and Safety/Tolerability Profile of CKD-379
A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination
- Trial name
- NCT05452525
- Testing
- CKD-379 I, CKD-379 II, D759+D745+D150
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral administration relative to 2.5-mg Saxagliptin and 5-mg…
- Trial name
- NCT02060201
- Testing
- Saxagliptin, Dapagliflozin, Saxagliptin/Dapagliflozin FDC
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
- Trial name
- NCT01662999
- Testing
- Saxagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects
To evaluate the single-dose subcutaneous injection of insulin degludec injection (Tresiba®) listed by Novo Nordisk in China as a reference drug, the insulin degludec injection provided by Dongguan Dongyang Sunshine…
- Trial name
- NCT05576298
- Testing
- Insulin degludec injection, RD15003, Insulin degludec, Tresiba
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Type 2 Diabetes Mellitus
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the second Phase 1 study with GSK376501 and the goal is to further evaluate its safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00495014
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with…
- Trial name
- NCT00184626
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- Turkey (Türkiye)
- Volunteers
- 97 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan
To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).
- Trial name
- NCT01318135
- Testing
- Alogliptin and glimepiride, Alogliptin and metformin
- Volunteers
- 576 people
- Sponsor
- Takeda
Chronic Kidney Diseases, Type 1 Diabetes Mellitus
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys…
- Conditions
- Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- NCT05018416
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Prokidney
Diabetes Mellitus, Type 2, Insulin Resistance
Day-night Rhythm in Muscle Metabolism of Prediabetics
This study evaluates the existence of a day-night rhythm in skeletal muscle energy metabolism in prediabetic subjects. Subjects will stay at the research facility for 44 hours with a standardized living protocol during which…
- Trial name
- NCT03733743
- Testing
- Standardized living protocol
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Maastricht University
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under normal clinical practice…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00700648
- Testing
- insulin aspart
- Where
- India
- Volunteers
- 3,024 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, CV Risk
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
- Trial name
- NCT00648284
- Volunteers
- 1,100 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of multiple oral doses of DBPR108 in healthy male subjects.
- Trial name
- NCT02163278
- Testing
- DBPR108
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This observational study is conducted in North America. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00706017)
- Testing
- insulin detemir
- Where
- Mexico
- Volunteers
- 2,282 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study of NovoNorm® in Subjects With Diabetes
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.
- Trial name
- NCT01498913
- Testing
- repaglinide
- Where
- South Korea
- Volunteers
- 5,841 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.